BeOne Medicines

BeOne Medicines

Yahoo Finance • 15 hours ago

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphoma Application supported by Phase 3 MANGROVE data, showing a 43... Full story

Yahoo Finance • 12 days ago

BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.

Oncology-focused biotech firm BeOne Medicines explores buy zone, boosted by strong demand and stellar earnings growth. Continue Reading... Full story

Yahoo Finance • 14 days ago

BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.

Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth. Continue Reading... Full story

Yahoo Finance • 2 months ago

Goldman picks China healthcare stocks for a post-AI trade

Chinese corporate earnings are on a tear, giving investors clues on which stock sectors offer untapped returns, according to Goldman Sachs. Nearly half of MSCI China index constituents beat estimates in the second quarter, with IT and heal... Full story

Yahoo Finance • 2 months ago

BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher shar... Full story

Yahoo Finance • 2 months ago

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more th... Full story

Yahoo Finance • 2 months ago

AM Markets Need to Know: Nasdaq rebounds in August, Anthropic expands AI capacity, and more

[New York City and London multiple exposure image] Stock index futures pointed to a weaker open on Tuesday, setting Wall Street up for a lower start to September as investors monitored renewed tensions in the Middle East. Here are the fi... Full story

Yahoo Finance • 2 months ago

BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

SAN CARLOS, Calif., September 01, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference... Full story

Yahoo Finance • 3 months ago

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biote... Full story

Yahoo Finance • 3 months ago

Summit higher as partner Akeso wins China label expansion for lead drug

[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansi... Full story

Yahoo Finance • 3 months ago

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. S... Full story

Yahoo Finance • 3 months ago

State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?

Key Points State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to the 0.55% charged by First Trust NYSE Arca Biotechnology Index Fund. First Trust's fund focuses exclusively on 30 b... Full story

Yahoo Finance • 3 months ago

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

The First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides concentrated, high-conviction exposure to biotechnology firms, while the Vanguard Health Care ETF (NYSEMKT:VHT) offers a cheaper, diversified basket across the entir... Full story

Yahoo Finance • 3 months ago

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position

Key Points CEO John Oyler sold nearly 110,000 American Depositary Shares for $34.6 million at a weighted average price of $315.28 per share. The shares were sold under a pre-established Rule 10b5-1 trading plan. John Oyler retains Ordinar... Full story

Yahoo Finance • 4 months ago

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

Key Points iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio... Full story

Yahoo Finance • 4 months ago

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

Quick Read SK hynix surged 13% on its Nasdaq debut, raising $26.5 billion in what stands as the largest U.S. equity sale by a foreign company ever. Circle Internet Group (CRCL) surged 15% on OCC bank approval as Capital One (COF) earned a... Full story

Yahoo Finance • 4 months ago

Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list. TheFly reported on June 2 that RBC Capital analyst Leon... Full story

Yahoo Finance • 4 months ago

Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth

(RTTNews) - Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth, who has served as Chairman of Kymera sinc... Full story

Yahoo Finance • 4 months ago

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made... Full story

Yahoo Finance • 5 months ago

BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA

BeOne Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, BeOne Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approv... Full story